Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis

Abudurexiti,Mierxiati; Zhu,Yao; Ye,Ding‑Wei

doi:10.3892/mco.2020.2057

Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis

Authors:
- Mierxiati Abudurexiti
- Yao Zhu
- Ding‑Wei Ye
View Affiliations

Affiliations: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
Published online on: June 3, 2020 https://doi.org/10.3892/mco.2020.2057
Pages: 146-154
Copyright: © Abudurexiti et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the clinical significance afforded by locoregional surgery in improving the prognosis of primary metastatic testicular cancer (pMTC). The population‑based Surveillance, Epidemiology and End Results database was used as the primary source of data in the present study. Stratification analysis was employed to identify the effects of testicular surgery on testicular cancer‑specific survival and overall survival. Propensity score matching and Cox regression models were then employed to find and evaluate the extent of improvements to the survival of patients with pMTC by testicular surgery. The median testicular cancer‑specific survival and overall survival in the surgery group were 10% higher than those in the group without surgery. Testicular surgery was demonstrated to have provided a survival advantage for patients with a single metastasis in the bone or brain, but not in the liver or lung. When combined with radiotherapy and chemotherapy, surgery significantly improved the survival of patients. However, according to the surgical outcome based on molecular subtypes, when deciding on the surgery for patients with metastatic testicular cancer, only human chorionic gonadotropin and lactate dehydrogenase, and not α‑fetoprotein should be considered. Surgery serves a significant role in the management of non‑seminoma, whereas its role in the management of seminoma is far more limited. The effects of locoregional surgery have been neglected when treating patients with pMTC. Surgical procedures should be considered more seriously when planning combination treatments for patients with pMTC with a single bone or brain metastasis.

View Figures

View References

1	International Agency for Research on Cancer (IARC): Estimated number of new cases in 2018, testis, males, all ages. https://gco.iarc.fr/today/online-analysis-table?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=1&cancer=28&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1. Accessed September 20, 2019.
2	Spiekermann M, Dieckmann KP, Balks T, Bullerdiek J and Belge G: Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors? Anticancer Res. 35:117–121. 2015.PubMed/NCBI
3	Hjelle LV, Gundersen PO, Oldenburg J, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Bremnes RM and Haugnes HS: Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: A 20-year follow-up study. Anticancer Res. 35:1619–1625. 2015.PubMed/NCBI
4	Burczynska BB, Kobrouly L, Butler SA, Naase M and Iles RK: Novel insights into the expression of CGB1 & 2 genes by epithelial cancer cell lines secreting ectopic free hCGβ. Anticancer Res. 34:2239–2248. 2014.PubMed/NCBI
5	Li X, Huang R, Ma L, Liu S and Zong X: Locoregional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasis. Breast. 45:104–112. 2019.PubMed/NCBI View Article : Google Scholar
6	Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH, Brenner H and Coebergh JW: Clinical relevance of conditional survival of cancer patients in europe: Age-specific analyses of 13 cancers. J Clin Oncol. 28:2520–2528. 2010.PubMed/NCBI View Article : Google Scholar
7	Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L and Kunkler I: EUROCARE-4 Working Group. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007.PubMed/NCBI View Article : Google Scholar
8	International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 15:594–603. 1997.PubMed/NCBI View Article : Google Scholar
9	Baird DC, Meyers GJ and Hu JS: Testicular cancer: Diagnosis and treatment. Am Fam Physician. 97:261–268. 2018.PubMed/NCBI
10	Goedert JJ, Purdue MP, McNeel TS, McGlynn KA and Engels EA: Risk of germ cell tumors among men with HIV/acquired immunodeficiency syndrome. Cancer Epidemiol Biomarkers Prev. 16:1266–1269. 2007.PubMed/NCBI View Article : Google Scholar
11	Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L, Bui NB, Pény J, Caty A, Delva R, et al: Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: A randomized trial of the genito-urinary group of the french federation of cancer centers (GETUG T93BP). Ann Oncol. 18:917–924. 2007.PubMed/NCBI View Article : Google Scholar
12	de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S and Collette L: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medical research council. J Clin Oncol. 19:1629–1640. 2001.PubMed/NCBI View Article : Google Scholar
13	Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR and Travis LB: Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: A population-based study. J Clin Oncol. 33:3105–3115. 2015.PubMed/NCBI View Article : Google Scholar
14	Fung C, Fossa SD, Williams A and Travis LB: Long-term morbidity of testicular cancer treatment. Urol Clin North Am. 42:393–408. 2015.PubMed/NCBI View Article : Google Scholar
15	Pfister D, Haidl F, Paffenholz P and Heidenreich A: Metastatic surgery in testis cancer. Curr Opin Urol. 26:590–595. 2016.PubMed/NCBI View Article : Google Scholar
16	Paffenholz P, Pfister D and Heidenreich A: Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours. Urologe A. 55:632–640. 2016.PubMed/NCBI View Article : Google Scholar : (In German).
17	Collis CH and Eckert H: Seminoma of the testis with bone involvement: A report of three cases. Clin Radiol. 36:467–468. 1985.PubMed/NCBI View Article : Google Scholar
18	Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, et al: Serum levels of microRNA miR-371a-3p: A sensitive and specific new biomarker for germ cell tumours. Eur Urol. 71:213–220. 2017.PubMed/NCBI View Article : Google Scholar